Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FKKF4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $83,729
Award facts
- Contract value 100% obligated
- $83,728.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a delivery order valued at $83,728.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. This firm fixed-price delivery order, awarded on December 9, 2025, with an ultimate completion date of December 31, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The order was funded by the DLA and will be performed at the vendor's Park Ridge, Illinois location.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion federal acquisition strategy designed to establish multiple regional prime vendor contractors for pharmaceutical supply to Department of Defense healthcare facilities worldwide. The parent IDC, awarded November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three optional 30-month renewal periods. DMS Pharmaceutical Group's established performance across multiple therapeutic categories, including oncology treatments and specialty pharmaceuticals, positions the company as a critical supplier within the federal military medical supply chain with no identified subcontractors.
Quick answers
Who was awarded contract SPE2DR26FKKF4?
SPE2DR26FKKF4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 9, 2025.
How much is contract SPE2DR26FKKF4 worth?
The government has obligated $83,729 on SPE2DR26FKKF4.
Is contract SPE2DR26FKKF4 an order under another contract?
Yes. SPE2DR26FKKF4 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKF4 competed?
The extent of competition for SPE2DR26FKKF4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award